EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

Trial Details

NCT ID

NCT06802835

Phase

PHASE1 / PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

EGFR Antibody
PD-1 antibody
Gemcitabine, Cisplatin
IMRT

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Patients with nasopharyngeal carcinoma who have recurred/metastasized after initial treatment or radical treatment;
Age 18-75, male or female;
Pathological diagnosis of nasopharyngeal carcinoma;
ECOG score 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →